TM Owner AstraZeneca
Tremelimumab IV 300mg/15ml Injection (solution for IV infusion, single-dose vial)
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Tremelimumab IV 300mg/15ml is not a marketed brand name; the medicine behind this catalogue entry is Imjudo (tremelimumab-actl), a CTLA-4-blocking monoclonal antibody made by AstraZeneca.
- Imjudo is approved only in combination with the PD-L1 inhibitor durvalumab: for adults with unresectable hepatocellular carcinoma (a form of liver cancer), and, together with durvalumab and platinum-based chemotherapy, for adults with metastatic non-small cell lung cancer without certain EGFR or ALK mutations.
- It is not approved alone.
- Tremelimumab has no oral, subcutaneous or intramuscular form; every approved presentation, including this 300 mg/15 mL vial, is given only as an intravenous infusion by a specialist team, so the word 'IV' here does not describe a separate product.
- This row is identical in drug, strength, pack, storage, origin and manufacturer to another catalogue entry named simply 'Tremelimumab'; the two rows most likely describe one product listed twice and should be reviewed together.
Side Effects
- Imjudo (tremelimumab-actl) has no boxed warning, but because it activates the immune system it can trigger immune-mediated inflammation in almost any organ, which matters more than routine side effects.
- Combined with durvalumab for liver cancer, over 20% of patients report rash, diarrhoea, fatigue, itching, muscle or joint pain and abdominal pain; for lung cancer, common effects include nausea, fatigue, muscle or joint pain, reduced appetite, rash and diarrhoea.
- Serious immune-mediated reactions - inflammation of the lungs, liver, bowel, thyroid, pituitary, adrenal glands, kidneys or skin - can appear weeks after a dose and become severe or life-threatening if untreated.
- Infusion-related reactions such as fever, chills, flushing or breathing trouble can occur during or shortly after the infusion.
- Tell your care team at once about new cough, breathlessness, severe diarrhoea, dark urine, yellowing skin, severe abdominal pain or unusual fatigue, since early treatment of immune-related reactions stops them becoming serious.
Precautions & Warnings
- Imjudo (tremelimumab-actl), given with durvalumab, is for intravenous infusion only under specialist supervision - it is never given as a subcutaneous or intramuscular injection or self-administered at home.
- Blood tests before and during treatment monitor liver enzymes, kidney function, thyroid hormones and adrenal (ACTH) levels, because immune-mediated inflammation of these organs can develop at any point and needs prompt steroid treatment when it occurs.
- Imjudo should not be started in people with active autoimmune disease needing systemic treatment, or in organ transplant recipients, without specialist discussion, since boosting the immune system can worsen these conditions or trigger rejection.
- Tremelimumab can cause fetal harm, so anyone who could become pregnant should use effective contraception during treatment and for at least 3 months after the last dose; breastfeeding is not recommended during treatment.
- Discuss any planned vaccination with the treating team before starting.
Avoid Interactions
- There is no specific food or over-the-counter interaction list for Imjudo (tremelimumab-actl), because as a monoclonal antibody it is not broken down by the liver's CYP450 enzymes that cause most small-molecule interactions.
- The main concern is other medicines that affect the immune system: corticosteroids or other immunosuppressants taken before starting may blunt Imjudo's anti-tumour effect, though they are still used to treat immune-related side effects once they occur.
- Live attenuated vaccines should generally be avoided during treatment.
- Imjudo must never be mixed or infused through the same intravenous line as other medicines - it is always given as its own diluted infusion.
- Tell your oncology team about every prescription, over-the-counter medicine, herbal product and supplement you take, and about any recent or planned vaccination, so infusions can be planned safely.
References
Frequently Asked Questions
Imjudo (tremelimumab), catalogued here as "Tremelimumab IV", treats unresectable liver cancer and metastatic non-small cell lung cancer in adults, always combined with durvalumab. It is not used alone. This 300 mg/15 mL vial is the only strength for the full adult loading dose.
Imjudo is given only as an intravenous infusion in a hospital or cancer clinic, usually over 60 minutes, alongside durvalumab. There is no injection, tablet or home-use form. Your oncology team sets the exact schedule based on your cancer type and body weight.
Common Imjudo (tremelimumab) side effects include rash, itching, diarrhoea, fatigue, and muscle or joint pain. More serious immune-mediated reactions can inflame the lungs, liver, bowel, thyroid or kidneys. Report new cough, breathlessness, severe diarrhoea, dark urine or yellowing skin to your care team urgently.
Avoid live vaccines while receiving Imjudo (tremelimumab) unless your oncologist approves them. Tell your care team about steroids or other immune-suppressing medicines, since these can reduce how well Imjudo works. Imjudo is never mixed with other drugs in the same infusion.
Imjudo is infused into a vein over about 60 minutes, followed by durvalumab, usually every 3 to 4 weeks in a monitored clinic setting. Staff watch for infusion reactions like fever, chills or breathing changes, and blood tests check organ function before each cycle.
Very likely yes. Both entries list the identical drug, 300 mg/15 mL strength, pack, storage, origin and manufacturer, and tremelimumab (Imjudo) is only ever given intravenously anyway. "IV" does not describe a different product, so this may be a duplicate listing.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
